|
Trinity Biotech Plc (NASDAQ: TRIB) |
|
Trinity Biotech Plc
TRIB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Trinity Biotech Plc's sales fell
by -24 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2376
In Vitro & In Vivo Diagnostic Substances industry recorded
deterioration of revenues by
Trinity Biotech Plc net loss decreased from $-41 millions, to $-37 millions in IV. Quarter 2023,
• More on TRIB's Growth
|
|
Trinity Biotech Plc realized a net loss in trailing twelve months.
Trinity Biotech Plc realized cash reduction of $ 0 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
419.13 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.1.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.85.
• More on TRIB's Valuation
|
|
|
|
|
Trinity Biotech Plc realized net loss in trailing twelve months.
Trinity Biotech Plc realized cash outflow of $ 0per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
419.13 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.1.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.85.
• More on TRIB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com